Triple negative breast cancer: a multi-omics network discovery strategy for candidate targets and driving pathways.


Triple negative breast cancer (TNBC) represents approximately 15% of breast cancers and is characterized by lack of expression of both estrogen receptor (ER) and progesterone receptor (PR), together with absence of human epidermal growth factor 2 (HER2). TNBC has attracted considerable attention due to its aggressiveness such as large tumor size, high… (More)
DOI: 10.1089/omi.2014.0135